Therefore, we concluded that DcR3 promotes placing HCC patients in an immunosuppressive state and that DcR3 may accelerate the development of HCC by suppressing the CD4+ T-cell immune response. Here, TNFRSF6B is linked to hepatocellular carcinoma.